Figure 1
Expression and intracellular distribution of Hsp16.2 in different human tumors of the nervous system. Immunohistochemistry utilizing anti-Hsp16.2 primary antibody was performed on 91 brain tumor samples. A. Schwannoma. Intensive intranuclear Hsp16.2 immunoreactivity, whereas no immunoreactivity in the cytoplasm. B. Pilocytic astrocytoma. Strong intranuclear immunopositivity but no intracytoplasmic staining was detected. C. Grade 2 astrocytoma shows intensive intranuclear labeling as well as mild cytoplasmic staining. D. Grade 3 astrocytoma exhibits strong Hsp 16.2 positivity intranuclearly and moderate Hsp16.2 positivity in the cytoplasm. E. Grade 1 meningeoma showing high expression of Hsp16.2 intranuclearly and mild expression in the cytoplasm. F. Grade 3 meningeoma displayed strong intranuclear and moderate cytoplasmic staining for Hsp16.2. G. Grade 2 ependymoma with strong intranuclear and moderate cytoplasmic immunopositivity. H. Grade 3 oligodendroglioma exhibiting intensive intranuclear and moderate cytoplasmic immunoreactivity. I. Grade 4 glioblastoma showing strong Hsp16.2 positivity intranuclearly and intracytoplasmically alike. J. Grade 4 PNET with intensive staining in the nucleus as well as in the cytoplasm.